
Biopta is able to research many functions in human skin and subcutaneous tissues. One of these key areas is the assessment of anti-inflammatory activity in fresh full thickness ex vivo human skin. We are able to source healthy fresh human skin several times a week, enabling us to rapidly assess your novel compounds and provide invaluable human efficacy data.
Inflammation Model
Our inflammation model is an ideal method of assessing the anti-inflammatory properties of your test compound in vitro, up to 60 conditions can be assessed using skin from a single donor allowing for a comparatively high throughput and quick turnaround. Test article can be added to the culture media or applied topically and the resultant changes in cytokines and other inflammatory mediators can be assessed by multiplex ELISA. For more information and some sample data click here...
This same model can also be used to assess the inflammatory effect of test articles. As the assay is viable for up to 6 days, repeated application of test article can be made and resultant cytokine changes can be assessed by multiplex ELISA.
Epidermal Hyperplasia Model
An assay which can be employed to assess your compounds ability to prevent epidermal hyperplasia in fresh full thickness human skin. Typically an 8 - 10 day assay with a minimum of two endpoints including histopathological quantification of epidermal hyperplasia and cytokine and inflammatory mediator analysis of culture supernatants. For more information and an overview of the validation experiment click here...